Advaxis publishes research content on Her2 antigen for Listeria vaccine Scientists in Advaxis, Inc., , the live, attenuated Listeria monocytogenes immunotherapy company, had their research using ADXS31-164 recently, a live Listeria vaccine that targets Her2, released in a leading peer examined journal . We hope to be in the clinic shortly with this agent to build up it for a number of cancer indications. This article presents research carried out with this novel energetic immunotherapy in various Her2 tumor models. Unlike antibodies that may only attack portions of antigens that are outside the cells, cellular immunotherapies like ADXS31-164 can strike the portions of the antigen that protrude in the cell aswell.Nearly 60 % of companies who offer coverage do not insure dependent kids over age group 18 or 19 if they do not attend university. Thirty-nine % of young adults age groups 19 to 23 who either usually do not attend university or just attend part-period are uninsured, weighed against 17 % of full-time students. Related StoriesSignostics gets FDA 510k clearance for handheld bladder scannerGreater evidence-structured help necessary for depressed employees – New report from The Work FoundationInnovative IV pole making use of polycarbonate resin blend from Bayer enhances patient and health care worker safetyIn the facial skin of these challenges, new initiatives on both state and federal level to cover young adults are gaining momentum.